{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T18:52:27Z","timestamp":1786474347583,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is responsible for significant disability and societal burden. Recently, drugs targeting the calcitonin gene-related peptide (CGRP) pathway raised new hopes. CGRP, a potent vasodilator, plays a key role in the pathogenesis of migraine attacks. The deficiency of CGRP is involved in Raynaud\u2019s phenomenon, which consists of abnormal vasoconstriction of the digits. We aimed to assess the potential association of Raynaud\u2019s phenomenon with CGRP-targeting drugs, analyzing real-world data from the World Health Organization (VigiBase\u00ae).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We queried all reports of Raynaud\u2019s phenomenon involving a CGRP-targeting drug. We sought disproportionate reporting of Raynaud\u2019s phenomenon with these drugs. For this purpose, we relied on the calculation of the Information Component (IC). A positive lower end of the 95% confidence interval (CI) of the IC defines a statistically significant association. As migraine patients are prone to Raynaud\u2019s phenomenon, we also calculated the IC of Raynaud\u2019s phenomenon with CGRP-targeting drugs compared to 5HT1<jats:sub>B\/D<\/jats:sub> agonists (triptans), and beta-blockers used in the treatment of migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 99 reports of Raynaud\u2019s phenomenon involving CGRP-targeting drugs have been yielded in VigiBase\u00ae. The most reported CGRP-targeting drug was erenumab, with 56 reports (56.6%). The median time to onset was 84\u2009days. No fatality was notified, but one patient suffered from gangrene and extremity necrosis. As a whole, CGRP-targeting drugs were significantly associated with Raynaud\u2019s phenomenon, with an IC of 3.3 (95%CI: 3.0\u20133.5). There was a disproportionate reporting of Raynaud\u2019s phenomenon with CGRP-targeting drugs compared to triptans (IC 0.4; 95%CI: 0.1\u20130.6) and to beta-blockers (IC 0.5; 95%CI: 0.2\u20130.7) as well.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There is a significant disproportionality signal of Raynaud\u2019s phenomenon with CGRP-targeting. This signal stands out when CGRP-targeting drugs are compared to other drugs used in patients with migraine. This study is limited by missing data in pharmacovigilance reports. CGRP-targeting drugs may be subject to Weber effect and reporting bias. Nonetheless, CGRP blockade might be the last straw that disrupts the physiological balance of vascular response in patients at-risk of Raynaud\u2019s phenomenon. Pending further data regarding vascular safety of CGRP-targeting drugs, caution is warranted in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01424-w","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:03:12Z","timestamp":1651579392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database"],"prefix":"10.1186","volume":"23","author":[{"given":"Alexandre O.","family":"G\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise K.","family":"Van Obberghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lant\u00e9ri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"1424_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","volume":"15","author":"EC Gross","year":"2019","unstructured":"Gross EC, Lisicki M, Fischer D et al (2019) The metabolic face of migraine \u2014 from pathophysiology to treatment. Nat Rev Neurol 15:627\u2013643. https:\/\/doi.org\/10.1038\/s41582-019-0255-4","journal-title":"Nat Rev Neurol"},{"key":"1424_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 211:107528. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","journal-title":"Pharmacol Ther"},{"key":"1424_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1129-2377-14-1","volume":"14","author":"TJ Steiner","year":"2013","unstructured":"Steiner TJ, Stovner LJ, Birbeck GL (2013) Migraine: the seventh disabler. J Headache Pain 14:1. https:\/\/doi.org\/10.1186\/1129-2377-14-1","journal-title":"J Headache Pain"},{"key":"1424_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH et al (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","journal-title":"Lancet"},{"key":"1424_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1526-4610.2007.00752.x","volume":"47","author":"M Bigal","year":"2007","unstructured":"Bigal M, Rapoport A, Aurora S et al (2007) Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache 47:475\u2013479. https:\/\/doi.org\/10.1111\/j.1526-4610.2007.00752.x","journal-title":"Headache"},{"key":"1424_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villal\u00f3n","year":"2009","unstructured":"Villal\u00f3n CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124:309\u2013323. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.09.003","journal-title":"Pharmacol Ther"},{"key":"1424_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","volume":"23","author":"I Urits","year":"2019","unstructured":"Urits I, Jones MR, Gress K et al (2019) CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep 23:29. https:\/\/doi.org\/10.1007\/s11916-019-0768-y","journal-title":"Curr Pain Headache Rep"},{"key":"1424_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies \u2014 successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"1424_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-022-01391-2","volume":"23","author":"X Tao","year":"2022","unstructured":"Tao X, Yan Z, Meng J et al (2022) The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain 23:19. https:\/\/doi.org\/10.1186\/s10194-022-01391-2","journal-title":"J Headache Pain"},{"key":"1424_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21:284\u2013294. https:\/\/doi.org\/10.1016\/S1474-4422(21)00409-9","journal-title":"Lancet Neurol"},{"key":"1424_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(21)00468-3","volume":"21","author":"HC Diener","year":"2022","unstructured":"Diener HC (2022) CGRP-targeted drugs for migraine: still many uncertainties. Lancet Neurol 21:209\u2013210. https:\/\/doi.org\/10.1016\/S1474-4422(21)00468-3","journal-title":"Lancet Neurol"},{"key":"1424_CR12","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","volume":"94","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Pascual J, Winner PK et al (2020) Vascular safety of erenumab for migraine prevention. Neurology 94:e497\u2013e510. https:\/\/doi.org\/10.1212\/WNL.0000000000008743","journal-title":"Neurology"},{"key":"1424_CR13","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1001\/jama.2020.7172","volume":"323","author":"T Kurth","year":"2020","unstructured":"Kurth T, Rist PM, Ridker PM et al (2020) Association of Migraine with Aura and Other Risk Factors with Incident Cardiovascular Disease in women. JAMA 323:2281\u20132289. https:\/\/doi.org\/10.1001\/jama.2020.7172","journal-title":"JAMA"},{"key":"1424_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/jnnp-2018-318254","volume":"91","author":"LR \u00d8ie","year":"2020","unstructured":"\u00d8ie LR, Kurth T, Gulati S, Dodick DW (2020) Migraine and risk of stroke. J Neurol Neurosurg Psychiatry 91:593\u2013604. https:\/\/doi.org\/10.1136\/jnnp-2018-318254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1424_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/head.13378","volume":"58","author":"JE Magalh\u00e3es","year":"2018","unstructured":"Magalh\u00e3es JE, Sampaio Rocha-Filho PA (2018) Migraine and cerebrovascular diseases: epidemiology, pathophysiological, and clinical considerations. Headache: the journal of head and face. Pain 58:1277\u20131286. https:\/\/doi.org\/10.1111\/head.13378","journal-title":"Pain"},{"key":"1424_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"Favoni V, Giani L, Al-Hassany L et al (2019) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 20:27. https:\/\/doi.org\/10.1186\/s10194-019-0979-y","journal-title":"J Headache Pain"},{"key":"1424_CR17","unstructured":"EMA AIMOVIG (erenumab): Summary of the risk management plan. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/aimovig-epar-risk-management-plan-summary_en.pdf. Accessed 1 Feb 2022"},{"key":"1424_CR18","unstructured":"EMA EMGALITY (galcanezumab): Summary of the risk management plan. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/emgality-epar-risk-management-plan-summary_en.pdf. Accessed 1 Feb 2022"},{"key":"1424_CR19","unstructured":"EMA AJOVY (fremanezumab): Summary of the risk management plan. https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/ajovy-epar-risk-management-plan-summary_en.pdf. Accessed 1 Feb 2022"},{"key":"1424_CR20","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-B","volume":"336","author":"CB Bunker","year":"1990","unstructured":"Bunker CB, Dowd PM, Terenghi G et al (1990) Deficiency of calcitonin gene-related peptide in Raynaud\u2019s phenomenon. Lancet 336:1530\u20131533. https:\/\/doi.org\/10.1016\/0140-6736(90)93307-B","journal-title":"Lancet"},{"key":"1424_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2133.1996.tb16221.x","volume":"134","author":"CB Bunker","year":"1996","unstructured":"Bunker CB, Goldsmith PC, Leslie TA et al (1996) Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud\u2019s phenomenon. Br J Dermatol 134:399\u2013406","journal-title":"Br J Dermatol"},{"key":"1424_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.1984.00350160096017","volume":"144","author":"I Zahavi","year":"1984","unstructured":"Zahavi I, Chagnac A, Hering R et al (1984) Prevalence of Raynaud\u2019s phenomenon in patients with migraine. Arch Intern Med 144:742\u2013744","journal-title":"Arch Intern Med"},{"key":"1424_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/ard.59.3.206","volume":"59","author":"PV Voulgari","year":"2000","unstructured":"Voulgari PV, Alamanos Y, Papazisi D et al (2000) Prevalence of Raynaud\u2019s phenomenon in a healthy Greek population. Ann Rheum Dis 59:206\u2013210. https:\/\/doi.org\/10.1136\/ard.59.3.206","journal-title":"Ann Rheum Dis"},{"key":"1424_CR24","doi-asserted-by":"publisher","unstructured":"Evans RW (2019) Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache: the journal of head and face. Pain 59(1360\u20131364). https:\/\/doi.org\/10.1111\/head.13596","DOI":"10.1111\/head.13596"},{"key":"1424_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7934","volume":"4","author":"ID Breen","year":"2021","unstructured":"Breen ID, Brumfiel CM, Patel MH et al (2021) Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open 4:e217934. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7934","journal-title":"JAMA Netw Open"},{"key":"1424_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4625","volume":"9","author":"AH Manickam","year":"2021","unstructured":"Manickam AH, Buture A, Tomkins E, Ruttledge M (2021) Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine. Clin Case Rep 9:e04625. https:\/\/doi.org\/10.1002\/ccr3.4625","journal-title":"Clin Case Rep"},{"key":"1424_CR27","unstructured":"VigiBase UMC | Analytics in VigiLyze. https:\/\/www.who-umc.org\/vigibase\/vigilyze\/analytics-in-vigilyze\/. Accessed 3 Sep 2021"},{"key":"1424_CR28","unstructured":"Welcome to MedDRA | MedDRA. https:\/\/www.meddra.org\/. Accessed 14 Nov 2020"},{"key":"1424_CR29","unstructured":"MedDRA Hierarchy | MedDRA. https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy. Accessed 3 Sep 2021"},{"key":"1424_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW (2009) Quantitative signal detection using spontaneous ADR reporting: QUANTITATIVE SIGNAL DETECTION. Pharmacoepidem Drug Safe 18:427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742","journal-title":"Pharmacoepidem Drug Safe"},{"key":"1424_CR31","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"1424_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"1424_CR33","unstructured":"FDA IMITREX (sumatriptan): label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020132s028,020626s025lbl.pdf. Accessed 1 Feb 2022"},{"key":"1424_CR34","doi-asserted-by":"publisher","first-page":"A44","DOI":"10.1016\/j.revmed.2015.03.273","volume":"36","author":"E Bouquet","year":"2015","unstructured":"Bouquet E, Lavigne C, Urbanski G, Lain\u00e9-Cessac P (2015) Les syndromes de Raynaud d\u2019origine m\u00e9dicamenteuse : analyse des donn\u00e9es de la base nationale de pharmacovigilance. La Revue de M\u00e9decine Interne 36:A44. https:\/\/doi.org\/10.1016\/j.revmed.2015.03.273","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"1424_CR35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1136\/bmj.1.6024.1498","volume":"1","author":"AJ Marshall","year":"1976","unstructured":"Marshall AJ, Roberts CJ, Barritt DW (1976) Raynaud\u2019s phenomenon as side effect of beta-blockers in hypertension. Br Med J 1:1498\u20131499. https:\/\/doi.org\/10.1136\/bmj.1.6024.1498","journal-title":"Br Med J"},{"key":"1424_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/bcp.12912","volume":"82","author":"C Khouri","year":"2016","unstructured":"Khouri C, Blaise S, Carpentier P et al (2016) Drug-induced Raynaud\u2019s phenomenon: beyond \u03b2-adrenoceptor blockers. Br J Clin Pharmacol 82:6\u201316. https:\/\/doi.org\/10.1111\/bcp.12912","journal-title":"Br J Clin Pharmacol"},{"key":"1424_CR37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1001\/jamainternmed.2021.2219","volume":"181","author":"L Renoud","year":"2021","unstructured":"Renoud L, Khouri C, Revol B et al (2021) Association of Facial Paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization Pharmacovigilance database. JAMA Intern Med 181:1243\u20131245. https:\/\/doi.org\/10.1001\/jamainternmed.2021.2219","journal-title":"JAMA Intern Med"},{"key":"1424_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604","journal-title":"Stat Methods Med Res"},{"key":"1424_CR39","doi-asserted-by":"publisher","first-page":"s18","DOI":"10.1007\/s101940300003","volume":"4","author":"GC Manzoni","year":"2003","unstructured":"Manzoni GC, Torelli P (2003) Epidemiology of migraine. J Headache Pain 4:s18\u2013s22. https:\/\/doi.org\/10.1007\/s101940300003","journal-title":"J Headache Pain"},{"key":"1424_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-021-01281-z","volume":"22","author":"V Caponnetto","year":"2021","unstructured":"Caponnetto V, Deodato M, Robotti M et al (2021) Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain 22:71. https:\/\/doi.org\/10.1186\/s10194-021-01281-z","journal-title":"J Headache Pain"},{"key":"1424_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/head.12482","volume":"55","author":"RC Burch","year":"2015","unstructured":"Burch RC, Loder S, Loder E, Smitherman TA (2015) The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache: the journal of head and face. Pain 55:21\u201334. https:\/\/doi.org\/10.1111\/head.12482","journal-title":"Pain"},{"key":"1424_CR42","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/art.20988","volume":"52","author":"LG Suter","year":"2005","unstructured":"Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud\u2019s phenomenon in the community. Arthritis Rheum 52:1259\u20131263. https:\/\/doi.org\/10.1002\/art.20988","journal-title":"Arthritis Rheum"},{"key":"1424_CR43","doi-asserted-by":"publisher","first-page":"P124","DOI":"10.1186\/1129-2377-14-S1-P124","volume":"14","author":"S Vermeersch","year":"2013","unstructured":"Vermeersch S, Frederiks P, Maassen VandenBrink A, de Hoon J (2013) Capsaicin-induced CGRP-mediated vasodilatation of the human skin: influence of gender, female hormones and migraine. J Headache Pain 14:P124. https:\/\/doi.org\/10.1186\/1129-2377-14-S1-P124","journal-title":"J Headache Pain"},{"key":"1424_CR44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/0333102419840780","volume":"39","author":"W Kielbasa","year":"2019","unstructured":"Kielbasa W, Helton DL (2019) A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia 39:1284\u20131297. https:\/\/doi.org\/10.1177\/0333102419840780","journal-title":"Cephalalgia"},{"key":"1424_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0140-6736(93)91286-U","volume":"342","author":"CB Bunker","year":"1993","unstructured":"Bunker CB, Reavley C, Dowd PM, O\u2019Shaughnessy DJ (1993) Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud\u2019s phenomenon. Lancet 342:80\u201383. https:\/\/doi.org\/10.1016\/0140-6736(93)91286-U","journal-title":"Lancet"},{"key":"1424_CR46","first-page":"171","volume":"23","author":"A Raynaud","year":"1994","unstructured":"Raynaud A, Cohen R, Modigliani E (1994) Calcitonin gene-related peptide (CGRP). Presse Med 23:171\u2013175","journal-title":"Presse Med"},{"key":"1424_CR47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1684\/ejd.2018.3300","volume":"28","author":"U Uslu","year":"2018","unstructured":"Uslu U, Streiff L, Sticherling M (2018) Systemic therapy with calcitonin has positive clinical effects on systemic sclerosis in patients with cutaneous manifestations. Eur J Dermatol 28:364\u2013369. https:\/\/doi.org\/10.1684\/ejd.2018.3300","journal-title":"Eur J Dermatol"},{"key":"1424_CR48","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie S-J et al (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94:1099\u20131142. https:\/\/doi.org\/10.1152\/physrev.00034.2013","journal-title":"Physiol Rev"},{"key":"1424_CR49","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1097\/00001756-199608120-00023","volume":"7","author":"L Arvieu","year":"1996","unstructured":"Arvieu L, Mauborgne A, Bourgoin S et al (1996) Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. Neuroreport 7:1973\u20131976. https:\/\/doi.org\/10.1097\/00001756-199608120-00023","journal-title":"Neuroreport"},{"key":"1424_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1129-2377-15-7","volume":"15","author":"C Kageneck","year":"2014","unstructured":"Kageneck C, Nixdorf-Bergweiler BE, Messlinger K, Fischer MJ (2014) Release of CGRP from mouse brainstem slices indicates central inhibitory effect of triptans and kynurenate. J Headache Pain 15:7. https:\/\/doi.org\/10.1186\/1129-2377-15-7","journal-title":"J Headache Pain"},{"key":"1424_CR51","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1177\/0333102419877169","volume":"39","author":"K Messlinger","year":"2019","unstructured":"Messlinger K, MaassenVanDenBrink A (2019) Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors \u2013 important studies on human isolated arteries. Cephalalgia 39:1731\u20131734. https:\/\/doi.org\/10.1177\/0333102419877169","journal-title":"Cephalalgia"},{"key":"1424_CR52","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(16)00019-3","volume":"15","author":"H Sun","year":"2016","unstructured":"Sun H, Dodick DW, Silberstein S et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:382\u2013390. https:\/\/doi.org\/10.1016\/S1474-4422(16)00019-3","journal-title":"Lancet Neurol"},{"key":"1424_CR53","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377:2123\u20132132. https:\/\/doi.org\/10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"1424_CR54","doi-asserted-by":"publisher","unstructured":"Mofid S, Bolislis WR, K\u00fchler TC (2022) Real-world data in the Postapproval setting as applied by the EMA and the US FDA. Clin Ther. https:\/\/doi.org\/10.1016\/j.clinthera.2021.12.010","DOI":"10.1016\/j.clinthera.2021.12.010"},{"key":"1424_CR55","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/01.CIR.89.1.366","volume":"89","author":"N Sekiguchi","year":"1994","unstructured":"Sekiguchi N, Kanatsuka H, Sato K et al (1994) Effect of calcitonin gene-related peptide on coronary microvessels and its role in acute myocardial ischemia. Circulation 89:366\u2013374. https:\/\/doi.org\/10.1161\/01.CIR.89.1.366","journal-title":"Circulation"},{"key":"1424_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/164_2019_204","volume-title":"Calcitonin gene-related peptide (CGRP) mechanisms: focus on migraine","author":"E Rubio-Beltr\u00e1n","year":"2019","unstructured":"Rubio-Beltr\u00e1n E, van den Brink AM (2019) Understanding CGRP and cardiovascular risk. In: Brain SD, Geppetti P (eds) Calcitonin gene-related peptide (CGRP) mechanisms: focus on migraine. Springer International Publishing, Cham, pp 131\u2013140"},{"key":"1424_CR57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00002018-200124030-00006","volume":"24","author":"EJ Wallenstein","year":"2001","unstructured":"Wallenstein EJ, Fife D (2001) Temporal patterns of NSAID spontaneous adverse event reports. Drug-Safety 24:233\u2013237. https:\/\/doi.org\/10.2165\/00002018-200124030-00006","journal-title":"Drug-Safety"},{"key":"1424_CR58","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP (2004) Replication of the weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24:743\u2013749. https:\/\/doi.org\/10.1592\/phco.24.8.743.36068","journal-title":"Pharmacotherapy"},{"key":"1424_CR59","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A et al (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases the notoriety Bias. Drug-Safety 30:891\u2013898. https:\/\/doi.org\/10.2165\/00002018-200730100-00007","journal-title":"Drug-Safety"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01424-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:03:23Z","timestamp":1651579403000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01424-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01424-w","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"26 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was not required for this observational study because the analysis was carried out on an anonymized pharmacovigilance database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML-M reports personal fee for advisory boards, speaker panels or investigation studies from Allergan, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, GlaxoSmithKline, Grunenthal, Lilly, Lundbeck, Medtronic, MSD, Novartis, Pfizer, ReckittBenckiser, Saint-Jude, Sanofi-Aventis, Teva, UCB, UPSA and Zambon.All other authors do declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}